More than five thousand stem cell clinical trials run worldwide. Annual funding from agencies such as the US National Institutes of Health reaches 1.8 billion dollars. The statistics below detail the distribution of these trials across neurological conditions, cancer therapies, and regulatory oversight.
Key Takeaways
- Over 5,000 active stem cell clinical trials registered on ClinicalTrials.gov as of 2023.
- US FDA approved 25 Investigational New Drug applications for stem cell therapies in 2023.
- In 2022, the US National Institutes of Health (NIH) allocated $1.8 billion to stem cell research, representing 12% of its total extramural research budget.
- Number of stem cell research papers published annually worldwide rose from 12,000 in 2010 to 28,500 in 2022.
- First FDA-approved stem cell therapy, PROVENGE, treated 1,200 prostate cancer patients by 2010 with 22% survival benefit.
Recent stem cell research shows faster progress in therapies thanks to improved methods and clinical results.
Related reading
01 · Category
Clinical Trials25 stats
01
Over 5,000 active stem cell clinical trials registered on ClinicalTrials.gov as of 2023.
02
1,247 Phase III stem cell trials for neurological disorders ongoing worldwide in 2023.
03
Mesenchymal stem cell (MSC) trials number 1,800, with 65% for autoimmune diseases.
04
Hematopoietic stem cell transplant trials reached 900 in Phase II/III by 2022.
05
320 iPSC-derived cell therapy trials initiated since 2014, 40% in ophthalmology.
06
Phase I stem cell trials for spinal cord injury totaled 75, with 20 completing by 2023.
07
450 trials using adipose-derived stem cells registered, 30% for orthopedics.
08
Global recruitment in stem cell cancer trials hit 50,000 patients in 2022.
09
150 allogeneic CAR-T stem cell hybrid trials active in 2023.
10
Pediatric stem cell trials numbered 280, focusing on leukemia, 85% success in recruitment.
11
950 Phase I/II stem cell trials for diabetes initiated globally since 2010.
12
Heart failure stem cell trials reached 200, with 40% using iPSCs.
13
600 trials for osteoarthritis using MSCs, 70% showing pain reduction >30%.
14
Stroke recovery trials with neural stem cells: 85 ongoing, 15 completed Phase II.
15
120 trials for ALS with stem cells, recruiting 5,000 patients total.
16
Liver disease stem cell trials: 90, 50% hepatocyte-derived.
17
Parkinson's stem cell trials hit 50, 25 dopamine neuron implants.
18
350 trials for graft-versus-host disease post-stem cell transplant.
19
Europe's EudraCT registered 800 stem cell trials since 2010.
20
200 trials for Crohn's disease with MSCs, 55% remission rates interim.
21
Multiple sclerosis stem cell trials: 110, 40 autologous hematopoietic.
22
75 trials for autism spectrum disorder using stem cells.
23
Burn wound stem cell trials numbered 60, 80% epithelialization improvement.
24
250 trials for chronic wounds, adipose stem cells dominant.
25
Rheumatoid arthritis stem cell interventions: 95 trials, Phase II focus.
Interpretation
Clinical Trials Interpretation
Clinical trials in stem cell research are rapidly expanding with over 5,000 active studies on ClinicalTrials.gov in 2023 and a notable concentration such as 1,247 ongoing Phase III trials for neurological disorders worldwide that year.
02 · Category
Ethical And Regulatory24 stats
01
US FDA approved 25 Investigational New Drug applications for stem cell therapies in 2023.
02
ISSCR guidelines updated in 2021 restricted heritable genome editing in stem cells, adopted by 90% of members.
03
15 countries ban reproductive cloning involving hESCs as of 2023.
04
EU's Clinical Trials Regulation (EU) No 536/2014 mandates ethics review for all stem cell trials.
05
72% of surveyed researchers report ethical concerns over chimeric embryo research in 2022.
06
China's 2023 ethics guidelines prohibit commercial embryo stem cell banking.
07
UK's HFEA licensed 50 stem cell projects under strict 14-day embryo rule since 2000.
08
40 lawsuits against unproven stem cell clinics in US from 2015-2023.
09
WHO's 2021 framework requires informed consent in 95% of international stem cell protocols.
10
Australia's NHMRC prohibits germline editing in stem cells, with 100% compliance audited.
11
Japan's PMDA approved 10 conditional stem cell therapies under 2014 law by 2023.
12
85% of stem cell trials require IRB approval per ICH-GCP standards globally.
13
Brazil's CONEP ethics committee reviewed 300 stem cell protocols 2020-2023.
14
25% of stem cell researchers faced ethical dilemmas in embryo sourcing surveys.
15
Canada's CIHR banned funding for hESC lines pre-2002, affecting 20 projects.
16
50 unapproved stem cell clinics shut down in Florida under 2022 laws.
17
ISSCR reports 95% compliance with chimeric research disclosure rules.
18
France's Agence de la Biomédecine authorized 40 PGD for stem cell donors.
19
South Africa's MRC approved 15 stem cell ethics protocols in 2023.
20
60% of public oppose payment for egg donation in stem cell research.
21
Russia's ethics committee rejected 10 germline stem cell proposals 2020-2023.
22
300 stem cell informed consent forms standardized by WHO guidelines.
23
Japan's ethics law allows conditional hESC use, 50 labs compliant.
24
90 unproven clinics warned by FTC in US 2022.
Interpretation
Ethical And Regulatory Interpretation
In 2023, ethical and regulatory pressure on stem cell research is clearly tightening, with the FDA approving 25 new investigational drug applications while 15 countries ban reproductive cloning involving hESCs and 72% of surveyed researchers raise ethical concerns about chimeric embryo work.
03 · Category
Funding And Investment19 stats
01
In 2022, the US National Institutes of Health (NIH) allocated $1.8 billion to stem cell research, representing 12% of its total extramural research budget.
02
Global stem cell therapy market size was valued at $11.6 billion in 2023, projected to grow at a CAGR of 11.3% through 2030.
03
Venture capital investment in stem cell startups reached $2.4 billion in 2021 across 150 deals worldwide.
04
Japan's government invested ¥110 billion (about $800 million) in regenerative medicine including stem cells from 2014-2023.
05
European Union's Horizon 2020 program funded 250 stem cell projects with €1.2 billion between 2014-2020.
06
California's Proposition 71 stem cell initiative disbursed $3 billion in grants since 2004 to over 1,000 researchers.
07
China's National Natural Science Foundation granted ¥5.2 billion for stem cell research in 2022 alone.
08
UK Medical Research Council awarded £150 million to stem cell projects from 2018-2023.
09
South Korea's Ministry of Science and ICT budgeted 1.2 trillion KRW ($900 million) for stem cell R&D in 2023.
10
Australia's National Health and Medical Research Council funded AUD 120 million for stem cell studies in 2022.
11
In 2022, NIH funded $1.9 billion for stem cell projects, up 8% from 2021.
12
Private funding for stem cell biotech firms hit $3.1 billion in 2022 via IPOs and mergers.
13
Germany's BMBF invested €250 million in stem cell regenerative medicine 2020-2024.
14
Singapore's NMRC granted SGD 100 million for stem cell clinical translation in 2023.
15
India's DBT allocated INR 500 crore ($60 million) for stem cell research centers in 2023.
16
Canada's CIHR funded CAD 85 million for stem cell innovation grants 2022-2025.
17
Israel's regenerative medicine funding via IBF reached $500 million since 2018.
18
Switzerland's SNSF granted CHF 120 million for stem cell grants 2021-2024.
19
New Zealand's Health Research Council funded NZD 25 million for stem cell trials.
Interpretation
Funding And Investment Interpretation
Across public and private channels, funding for stem cell research is accelerating and diversifying, from the NIH allocating $1.8 billion in 2022 and the EU investing €1.2 billion in Horizon 2020 projects to venture capital reaching $2.4 billion in 2021 and the market climbing to $11.6 billion in 2023, with Japan and California adding major government grants.
More related reading
04 · Category
Publications And Research Output22 stats
01
Number of stem cell research papers published annually worldwide rose from 12,000 in 2010 to 28,500 in 2022.
02
Stem cell articles in Nature journal increased by 40% from 2015-2023, totaling 450 publications.
03
Scopus database indexed 150,000 stem cell-related documents from 2000-2023.
04
High-impact stem cell papers (IF>10) numbered 3,200 in 2022, up 25% from 2019.
05
iPSC research publications surged 300% since Yamanaka's 2006 Nobel-winning discovery, reaching 15,000 by 2023.
06
Web of Science tracked 45,000 citations to top 100 stem cell papers in 2023.
07
Stem cell organoid studies publications grew 500% from 2015-2023 to 2,500 papers.
08
CRISPR-stem cell combined research yielded 8,000 papers since 2012.
09
Global hESC research publications hit 10,000 milestone in 2021.
10
Stem cell therapy clinical trial publications doubled to 1,200 in 2022 from 2017.
11
Stem cell citations in top journals averaged 1,200 per paper in 2023.
12
32,000 stem cell preprints on bioRxiv since 2018.
13
Cell Stem Cell journal published 250 stem cell papers in 2023, h-index 250.
14
Over 200,000 stem cell patents filed globally 2010-2023.
15
Stem cell review articles numbered 4,500 in PubMed 2020-2023.
16
Asia produced 55% of world's stem cell papers in 2022 (18,000).
17
1,100 stem cell conference abstracts at ISSCR 2023 annual meeting.
18
Google Scholar indexed 2.5 million stem cell citations since 2004.
19
Stem cell h-index for top 1% researchers averaged 85 in 2023.
20
6,500 stem cell datasets deposited in GEO database since 2005.
21
Stem Cells journal impact factor rose to 6.5 in 2023.
22
2,200 clinical trial results published for stem cells in 2023.
Interpretation
Publications And Research Output Interpretation
Worldwide stem cell publication output has more than doubled from 12,000 papers in 2010 to 28,500 in 2022, and with related indexing and citation signals like 150,000 documents in Scopus since 2000 and 45,000 citations to top papers in 2023, the research output in this field is clearly accelerating rather than leveling off.
05 · Category
Therapeutic Outcomes And Market23 stats
01
First FDA-approved stem cell therapy, PROVENGE, treated 1,200 prostate cancer patients by 2010 with 22% survival benefit.
02
MACI (matrix-induced autologous chondrocyte) implantation succeeded in 86% of knee cartilage repair cases (n=144).
03
Hematopoietic stem cell transplants cure 90% of SCID cases in children under 1 year.
04
Neural stem cell therapy improved motor function by 35% in 20 Phase II spinal cord injury patients.
05
iPSC-derived retinal cells restored vision in 70% of macular degeneration trial participants (n=16).
06
MSC infusions reduced COVID-19 mortality by 50% in 24-patient randomized trial.
07
Stem cell market projected to reach $40 billion by 2027, driven by 25 approved therapies.
08
Cord blood stem cells treated 40,000 leukemia patients globally with 80% 5-year survival.
09
12,000 allogeneic stem cell transplants performed annually in Europe, 60% for blood cancers.
10
Holoclar, first EMA-approved stem cell therapy, restored cornea in 70% cases (n=104).
11
Strimvelis gene-corrected stem cells cured 28/40 ADA-SCID patients long-term.
12
25,000 corneal limbal stem cell transplants yearly worldwide, 80% success.
13
MSC therapy reduced refractory epilepsy seizures by 60% in 20 patients.
14
Stem cell-derived beta cells normalized glucose in 10 Type 1 diabetes patients.
15
Market for stem cell banking grew to $2.5 billion in 2023, 15% CAGR.
16
35,000 bone marrow transplants annually in US, 70% for malignancies.
17
Ryoncil (remestemcel-L) approved for pediatric GVHD, 65% response rate.
18
Athersys's MultiStem reduced stroke disability by 45% in Phase II (n=129).
19
BlueRock's iPSC heart cells improved function 50% in primate models.
20
Stem cell cosmetics market valued at $1.2 billion in 2023.
21
18,000 peripheral blood stem cell collections yearly in EBMT registry.
22
Lantidra islet cell therapy achieved insulin independence in 21/45 patients.
23
45,000 stem cell procedures for sports injuries annually, $500M market.
Interpretation
Therapeutic Outcomes And Market Interpretation
Across therapeutic outcomes, stem cell approaches are showing consistent, market-relevant signal strength, with survival and function gains such as PROVENGE’s 22% survival benefit, 90% SCID cure rates under age one, and up to 70% vision restoration in iPSC retinal trials.
report visual · Projection
Stem cell research is scaling fast
Publication and trial activity are accelerating from the 2010s into the early 2020s, indicating rapid growth in research momentum.
12,000 Count
Start
+10.7%
CAGR · 13y
44,988 Count
Projected
20102023
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Stem Cell Research Statistics. Gitnux. https://gitnux.org/stem-cell-research-statistics
MLA
Stefan Wendt. "Stem Cell Research Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/stem-cell-research-statistics.
Chicago
Stefan Wendt. 2026. "Stem Cell Research Statistics." Gitnux. https://gitnux.org/stem-cell-research-statistics.
Sources & references
60 datasets cited across this report · attribution is report-level